NEWS not from the company. https://ih.advfn.com
Post# of 15624
(Total Views: 271)
Posted On: 02/13/2018 8:50:30 AM
NEWS not from the company.
https://ih.advfn.com/p.php?pid=nmona&arti...ymbol=OWCP
OWC Pharmaceutical Research Corp. (OTCQB: OWCP), through its wholly-owned Israeli subsidiary, One Word Cannabis Ltd., is conducting medical research and clinical trials, in full compliance with all international regulatory protocols, for the development and improvement of strains of medical cannabis specifically designed for the treatment of several illnesses/medical conditions.
OWC has also entered into an agreement with Mediq Innovation Partners for marketing OWC's topical psoriasis cream in Germany. OWC has also progressed on using specific dosages of its Cannabaniod-based products administered through soluble pills taken orally, with its initial focus on PTSD, multiple myeloma and topical treatment of burns in addition to psoriasis.
OWCP shares have recently consolidated and are currently trading at $.40 per share.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the subject company in this report to be materially different from the statements made herein.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. Information in this release is fact checked and produced on a best efforts basis. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. The subject Company has not compensated Traders News Source for the creation or dissemination of this report. Traders News Source is the party responsible for issuing the press release and for hosting the full analyst report on Traders News Source website.
NOT FINANCIAL ADVICE
Traders News Source makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Traders News Source is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Traders News Source whatsoever for any direct, indirect or consequential loss arising from the use of this document. Traders News Source expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Traders News Source does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
https://ih.advfn.com/p.php?pid=nmona&arti...ymbol=OWCP
OWC Pharmaceutical Research Corp. (OTCQB: OWCP), through its wholly-owned Israeli subsidiary, One Word Cannabis Ltd., is conducting medical research and clinical trials, in full compliance with all international regulatory protocols, for the development and improvement of strains of medical cannabis specifically designed for the treatment of several illnesses/medical conditions.
OWC has also entered into an agreement with Mediq Innovation Partners for marketing OWC's topical psoriasis cream in Germany. OWC has also progressed on using specific dosages of its Cannabaniod-based products administered through soluble pills taken orally, with its initial focus on PTSD, multiple myeloma and topical treatment of burns in addition to psoriasis.
OWCP shares have recently consolidated and are currently trading at $.40 per share.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the subject company in this report to be materially different from the statements made herein.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. Information in this release is fact checked and produced on a best efforts basis. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. The subject Company has not compensated Traders News Source for the creation or dissemination of this report. Traders News Source is the party responsible for issuing the press release and for hosting the full analyst report on Traders News Source website.
NOT FINANCIAL ADVICE
Traders News Source makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Traders News Source is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Traders News Source whatsoever for any direct, indirect or consequential loss arising from the use of this document. Traders News Source expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Traders News Source does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
(0)
(0)OWC Pharmaceutical Research Corp. (OWCP) Stock Research Links
Scroll down for more posts ▼